Replies to post #25119 on Revive Therapeutics Ltd (RVVTF)

[ragstorum]

Absolutely, Longhorn. Good chance that Bucillamine and Molnupiravir are on that shortlist, with my bet on buc hitting the finish line first.

Despite the hype machine that Merck is trying to build around mol right now, their Phase3 may run into snags.

(repost)
https://www.clinicaltrialsarena.com/comment/ridgeback-mercks-molnupiravir-for-covid-19-has-moa-administration-advantages-but-phase-iia-faces-execution-obstacles-may-have-value-gaps/

[Classic Warrior]

Yes, it is so buy more and more and more. Something good will be here soon. Revive has a lot going on during the first quarter alone and for there to be no news on the additional sites, psychedelic studies, or from the 210 patients leads me to believe that something major is in the works and they need to be mum for a few more days.

ps. Rubber- I will go 50/50 with you on your pepto bismol stock. Let's go!!

[LonghornSean]

Dr. Yo, Yo, Yo lists Bucillamine as his first guess of Gottlieb's game changers. Load Up on Monday boys! Lets Go!!

https://twitter.com/yodoctoryo/status/1370582005965017088?s=21